Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23183624 | 0.89 | LPL (0.39) | CA2ALDH1A1HSD17B10KMT2APLK1 | |
| SCHEMBL19786365 | 0.85 | SIGMAR1 (0.41) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL21175628 | 0.84 | CA2 (0.52) | SMN1; SMN2CA2CA1ALDH1A1HSD17B10 | |
| SCHEMBL19771023 | 0.81 | ACACB (0.35) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL2608901 | 0.81 | KCNH2 (0.49) | HPGD | |
| SCHEMBL2408318 | 0.79 | TAAR1 (0.42) | LMNAHTR2A | |
| SCHEMBL23182837 | 0.79 | AOC3 (0.44) | HPGDSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL31651134 | 0.79 | ESR1 (0.48) | SMN1; SMN2NPC1RAB9ACA2ALDH1A1 | |
| SCHEMBL21305393 | 0.79 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1HSD17B10ESR1ADRA2A | |
| SCHEMBL2608896 | 0.79 | NQO1 (0.48) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944632-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ESR2, ESRRB, ESRRA | SMN1; SMN2 2369/4885NPC1 186/4885RAB9A 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.